References
- Yamamoto-FurushoJKPodolskyDKInnate immunity in inflammatory bowel diseaseWorld J Gastroenterol2007135577558017948931
- BernsteinCNShanahanFDisorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseasesGut20085791185119118515412
- GohKXiaoSDInflammatory bowel disease: a survey of the epidemiology in AsiaJ Dig Dis2009101619236540
- TorresEADe JesúsRPérezCMPrevalence of inflammatory bowel disease in an insured population in Puerto Rico during 1996P R Health Sci J20032225325814619451
- Yamamoto-FurushoJKClinical epidemiology of ulcerative colitis in Mexico: a single hospital-based study in a 20-year period (1987–2006)J Clin Gastroenterol20094322122419057395
- NgSCTangWChingJYIncidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn’s and colitis epidemiology studyGastroenterology201314515816523583432
- ParenteJMCoyCSCampeloVInflammatory bowel disease in an underdeveloped region of Northeastern BrazilWorld J Gastroenterol2015211197120625632193
- SilverbergMSSatsangiJAhmadTToward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of GastroenterologyCan J Gastroenterol200519Suppl A5A36A
- GerichMEMcGovernDPTowards personalized care in IBDNat Rev Gastroenterol Hepatol20141128729924345887
- Yamamoto-FurushoJKFonseca-CamarilloGGenetic markers associated with clinical outcomes in patients with inflammatory bowel diseaseInflamm Bowel Dis2015212683269526244649
- QuetglasEGMujagicZWiggeSUpdate on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel diseaseWorld J Gastroenterol201521125191254326640330
- KirchheinerJFuhrUBrockmöllerJPharmacogenetics-based therapeutic recommendations – ready for clinical practice?Nat Rev Drug Discov2005463964716056390
- KatsanosKHPapadakisKAPharmacogenetics of inflammatory bowel diseasePharmacogenomics2014152049206225521361
- LawsonMMThomasAGAkobengAKTumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis [review]Cochrane Database Syst Rev20063CD005112
- Yamamoto-FurushoJKPeñaloza-CoronelASánchez-MuñozFBarreto-ZúñigaRDomínguez-LópezAPeroxisome proliferator-activated receptor-gamma (PPAR gamma) expression is downregulated in patients with active ulcerative colitisInflamm Bowel Dis20111768068120848495
- Yamamoto-FurushoJKJacintez-CazaresMFuruzawa-CarballedaJFonseca-CamarilloGPeroxisome proliferator-activated receptors family is involved in the response to treatment and mild clinical course in patients with ulcerative colitisDis Markers2014201493253025548431
- ProhászkaZFüstGImmunological aspects of heat-shock proteins – the optimum stress of lifeMol Immunol200441294415140573
- RodolicoVTomaselloGZerilliMHsp60 and Hsp10 increase in colon mucosa of Crohn’s disease and ulcerative colitisCell Stress Chaperones20101587788420390473
- TomaselloGRodolicoVZerilliMChanges in immunohistochemical levels and subcellular localization after therapy and correlation and colocalization with CD68 suggest a pathogenetic role of Hsp60 in ulcerative colitisAppl Immunohistochem Mol Morphol20111955256121441812
- TomaselloGSciuméCRappaFHsp10, Hsp70, and Hsp90 immunohistochemical levels change in ulcerative colitis after therapyEur J Histochem201155e3822297444
- GabryelMSkrzypczak-ZielinskaMKucharskiMASlomskiRDobrowolskaAThe impact of genetic factors on response to glucocorticoids therapy in IBDScand J Gastroenterol20165165466526776488
- AnneseVValvanoMRPalmieriOMultidrug resistance 1 gene in inflammatory bowel disease: a meta-analysisWorld J Gastroenterol2006123636364416773678
- FarrellRJMurphyALongAHigh multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapyGastroenterology200011827928810648456
- Yamamoto-FurushoJKVilleda-RamírezMAFonseca-CamarilloGHigh gene expression of MDR1 (ABCB1) is associated with medical treatment response and long term remission in patients with ulcerative colitisInflamm Bowel Dis20101654171919714749
- HondaMOriiFAyabeTExpression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid-resistant ulcerative colitisGastroenterology200011885986610784585
- FujishimaSTakedaHKawataSYamakawaMThe relationship between the expression of the glucocorticoid receptor in biopsied colonic mucosa and the glucocorticoid responsiveness of ulcerative colitis patientsClin Immunol200913320821719646928
- Yamamoto-FurushoJKSantiago-HernándezJJPérez-HernándezNRamírez-FuentesSFragosoJMVargas-AlarcónGInterleukin 1β (IL-1B) and IL-1 antagonist receptor (IL-1RN) gene polymorphisms are associated with the genetic susceptibility and steroid dependence in patients with ulcerative colitisJ Clin Gastroenterol20114553153520975573
- Montero-MeléndezTLlorXGarcía-PlanellaEPerrettiMSuárezAIdentification of novel predictor classifiers for inflammatory bowel disease by gene expression profilingPLoS One20138e7623524155895
- Villeda RamírezMAMendivil RangelEJDomínguez LópezAYamamoto-FurushoJKInterleukin-18 upregulation is associated with the use of steroids in patients with ulcerative colitisInflamm Bowel Dis201117E50E5121456035
- DubinskyMCAzathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safetyClin Gastroenterol Hepatol2004273174315354273
- SchaeffelerELangTZangerUMEichelbaumMSchwabMHigh-throughput genotyping of thiopurine S-methyltransferase by denaturing HPLCClin Chem20014754855511238310
- SchaeffelerEFischerCBrockmeierDComprehensive analysis of thiopurine S-methyltransferase phenotype–genotype correlation in a large population of German-Caucasians and identification of novel TPMT variantsPharmacogenetics20041440741715226673
- ReutherLOSonneJLarsenNDahlerupJFThomsenOOSchmiegelowKThiopurine methyltransferase genotype distribution in patients with Crohn’s diseaseAliment Pharmacol Ther200317656812492733
- YatesCRKrynetskiEYLoennechenTMolecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intoleranceAnn Intern Med19971266086149103127
- AnsariAHassanCDuleyJThiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel diseaseAliment Pharmacol Ther2002161743175012269967
- KurzawskiMGawronska-SzklarzBDrozdzikMFrequency distribution of thiopurine S-methyltransferase alleles in a Polish populationTher Drug Monit20042654154515385838
- KubotaTChibaKFrequencies of thiopurine S-methyltransferase mutant alleles (TPMT*2, *3A, *3B and *3C) in 151 healthy Japanese subjects and the inheritance of TPMT*3C in the family of a propositusBr J Clin Pharmacol20015147547711422006
- AmeyawMMCollie-DuguidESPowrieRHOfori-AdjeiDMcLeodHLThiopurine methyltransferase alleles in British and Ghanaian populationsHum Mol Genet199983673709931345
- HeapGAWeedonMNBewsheaCMHLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressantsNat Genet2014461131113425217962
- LennardLTPMT in the treatment of Crohn’s disease with azathioprineGut20025114314612117866
- DubinskyMCLamotheSYangHYPharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel diseaseGastroenterology200011870571310734022
- WeinshilboumRMSladekSLMercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activityAm J Hum Genet1980326516627191632
- MoonWLoftusEVJrReview article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel diseaseAliment Pharmacol Ther Epub2016214
- FongSCBlakerPAArenas-HernandezMMarinakiAMSandersonJDGetting the best out of thiopurine therapy: thiopurine S-methyltransferase and beyondBiomark Med20159516525605455
- StoccoGPelinMFrancaRPharmacogenetics of azathioprine in inflammatory bowel disease: a role for glutathione-S-transferase?World J Gastroenterol2014203534354124707136
- StoccoGMartelossiSBarabinoAGlutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel diseaseInflamm Bowel Dis200713576417206640
- DervieuxTBoulieuRSimultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLCClin Chem1998445515559510860
- StoccoGCuzzoniEDe IudicibusSDeletion of glutathione-S-transferase M1 reduces azathioprine metabolite concentrations in young patients with inflammatory bowel diseaseJ Clin Gastroenterol201448435123787247
- DubinskyMCLamotheSYangHYPharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel diseaseGastroenterology200011870571310734022
- OstermanMTKunduRLichtensteinGRLewisJDAssociation of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysisGastroenterology20061301047105316618398
- HindorfULindqvistMHildebrandHFagerbergUAlmerSAdverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel diseaseAliment Pharmacol Ther20062433134216842460
- YarurAJAbreuMTDeshpandeARKermanDHSussmanDATherapeutic drug monitoring in patients with inflammatory bowel diseaseWorld J Gastroenterol2014203475348424707130
- Prieto-PérezRAlmogueraBCabaleiroTHakonarsonHAbad-SantosFAssociation between genetic polymorphisms and response to anti-TNFs in patients with inflammatory bowel diseaseInt J Mol Sci20161722526861312
- HlavatyTPierikMHenckaertsLPolymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn’s diseaseAliment Pharmacol Ther20052261362616181301
- MoroiREndoKKinouchiYFCGR3A-158 polymorphism influences the biological response to infliximab in Crohn’s disease through affecting the ADCC activityImmunogenetics20136526527123358932
- KoderSRepnikKFerkoljIGenetic polymorphism in ATG16l1 gene influences the response to adalimumab in Crohn’s disease patientsPharmacogenomics20151619120425712183
- JürgensMLaubenderRPHartlFDisease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitisAm J Gastroenterol20101051811181920197757
- BankSAndersenPSBurischJAssociations between functional polymorphisms in the NFB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel diseasePharmacogenom J201414526534
- FujinoSAndohABambaSIncreased expression of interleukin 17 in inflammatory bowel diseaseGut2013526570
- AfifWLoftusEVJrFaubionWAClinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel diseaseAm J Gastroenterol20101051133113920145610
- BortlikMDuricovaDMalickovaKInfliximab trough levels may predict sustained response to infliximab in patients with Crohn’s diseaseJ Crohns Colitis2013773674323200919
- Van MoerkerckeWAckaertCCompernolleGHigh infliximab trough levels are associated with mucosal healing in Crohn’s diseaseGastroenterology2010138S60
- BaertFNomanMVermeireSInfluence of immunogenicity on the long-term efficacy of infliximab in Crohn’s diseaseN Engl J Med200334860160812584368
- RoblinXMarotteHRinaudoMAssociation between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseasesClin Gastroenterol Hepatol201412808423891927
- YarurAJJainAHauensteinSIHigher adalimumab levels are associated with histologic and endoscopic remission in patients with Crohn’s disease and ulcerative colitisInflamm Bowel Dis20162240941526752470
- SeowCHNewmanAIrwinSPSteinhartAHSilverbergMSGreenbergGRTrough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitisGut201059495419651627
- KarmirisKPaintaudGNomanMInfluence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s diseaseGastroenterology20091371628164019664627
- NandaKSCheifetzASMossACImpact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysisAm J Gastroenterol2013108404723147525
- VelayosFSSheibaniSLocktonSPrevalence of antibodies to adalimumab (ATA) and correlation between ATA and low serum drug concentration on CRP and clinical symptoms in a prospective sample of IBD patientsGastroenterology2013144S91
- TewGWHackneyJAGibbonsDAssociation between response to etrolizumab and expression of integrin αE and granzyme A in colon biopsies of patients with ulcerative colitisGastroenterology201615047748726522261
- SwidsinskiALadhoffAPernthalerAMucosal flora in inflammatory bowel diseaseGastroenterology2002122445411781279
- PhilpottDJGirardinSECrohn’s disease-associated Nod2 mutants reduce IL10 transcriptionNat Immunol20091045545719381138
- FrankDNRobertsonCEHammCMDisease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseasesInflamm Bowel Dis20111717918420839241
- RauschPRehmanAKunzelSColonic mucosa-associated microbiota is influenced by an interaction of Crohn disease and FUT2 (secretor) genotypeProc Natl Acad Sci U S A2011108190301903522068912
- LuppCRobertsonMLWickhamMEHost-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of EnterobacteriaceaeCell Host Microbe2007211912918005726
- Darfeuille-MichaudABoudeauJBuloisPHigh prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s diseaseGastroenterology200412741242115300573
- SokolHLepagePSeksikPDoreJMarteauPTemperature gradient gel electrophoresis of fecal 16S rRNA reveals active Escherichia coli in the microbiota of patients with ulcerative colitisJ Clin Microbiol2006443172317716954244
- OhkusaTSatoNOgiharaTMoritaKOgawaMOkayasuIFusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibodyJ Gastroenterol Hepatol20021784985312164960
- OhkusaTYoshidaTSatoNWatanabeSTajiriHOkayasuICommensal bacteria can enter colonic epithelial cells and induce proinflammatory cytokine secretion: a possible pathogenic mechanism of ulcerative colitisJ Med Microbiol20095853554519369513
- AtarashiKTanoueTOshimaKTreg induction by a rationally selected mixture of Clostridia strains from the human microbiotaNature201350023223623842501
- LlopisMAntolinMCarolMLactobacillus casei downregulates commensals’ inflammatory signals in Crohn’s disease mucosaInflamm Bowel Dis20091527528318839424
- SokolHPigneurBWatterlotLFaecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patientsProc Natl Acad Sci U S A2008105167311673618936492
- WillingBHalfvarsonJDicksvedJTwin studies reveal specific imbalances in the mucosa associated microbiota of patients with ileal Crohn’s diseaseInflamm Bowel Dis20091565366019023901
- VarelaEManichanhCGallartMColonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitisAliment Pharmacol Ther20133815116123725320
- PascalVPozueloMBorruelNA microbial signature for Crohn’s diseaseGut201766581382228179361
- MoayyediPSuretteMGKimPTFecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trialGastroenterology20151102109
- RossenNGFuentesSvan der SpekMJFindings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitisGastroenterology20151110118